Maternal Self-efficacy and Motor Development in Premature Infants: Clinical Trial Protocol
Launched by UNIVERSIDAD DE LA SABANA · May 14, 2024
Trial Information
Current as of July 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special program can help mothers of premature babies feel more confident in caring for their infants and support their babies' motor development. The researchers want to see if this new approach, which focuses on boosting mothers' self-efficacy—essentially their belief in their ability to care for their children—can offer better outcomes compared to the usual care program known as the kangaroo care program. This trial will take place in Bogotá and Tunja, involving 92 mothers and their premature infants.
To be eligible for this study, mothers need to have a baby born prematurely (between 32 to 36.6 weeks of pregnancy) and be part of the outpatient kangaroo mother program in Bogotá, Tunja, or Zipaquirá during 2024 and 2025. Mothers with certain mental health issues or babies with specific medical conditions will not be able to participate. If you join the study, you'll receive support both in a clinic setting and at home, and your progress will be monitored over eight weeks to see how well the program works for you and your baby.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mothers of a child born prematurely who attend the outpatient kangaroo mother program in Bogotá, Tunja and Zipaquirá in the period between 2024 and 2025.
- • Premature children between 32 to 36.6 weeks who participate in the outpatient kangaroo mother program in Bogotá, Tunja and Zipaquirá in the period between 2024 and 2025.
- Exclusion Criteria:
- • Mothers who manifest any diagnosed mental limitation to participate in the study.
- • Premature children with hemodynamic alterations, congenital malformations, chromosomal syndromes, esophageal atresia, ductus arteriovenosus, heart disease and neurological pathologies.
About Universidad De La Sabana
Universidad de La Sabana is a leading academic institution in Colombia, recognized for its commitment to advancing healthcare research and education. With a strong emphasis on innovation and interdisciplinary collaboration, the university conducts clinical trials aimed at improving patient outcomes and addressing pressing health challenges. Its dedicated research team, equipped with state-of-the-art facilities, adheres to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its studies. Through these efforts, Universidad de La Sabana contributes significantly to the global body of medical knowledge and fosters the development of effective therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Angélica Ospina, PhD
Principal Investigator
Universidad de la Sabana
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported